John P. McLaughlin
John P. McLaughlin has served as a Director since June 2007. Since December 2008, Mr. McLaughlin has been President and Chief Executive Officer of PDL BioPharma, Inc., a publicly traded biotechnology company. From 2000 to 2008, he was Chief Executive Officer and a member of the Board of Directors of Anesiva, Inc, a biotechnology company. Prior to Anesiva, he was President of Tularik, and before that spent 11 years at Genentech in a number of senior management positions including Executive Vice President. Previously, Mr. McLaughlin represented pharmaceutical companies as a partner in a Washington, D.C. law firm that specializes in food and drug law and served as legal counsel to various subcommittees in the U.S. House of Representatives, drafting numerous measures that became U.S. Food and Drug Administration laws. Mr. McLaughlin was co-founder and Chairman of the board of Eyetech Pharmaceuticals, Inc., which was acquired by OSI Pharmaceuticals in 2005. He also co-founded and served as a director of Peak Surgical, which was acquired by Medtronic, and served as a director of AxoGen, Inc. Mr. McLaughlin currently serves as a director of Avalanche Biotechnologies, Inc. in addition to Seattle Genetics.
He earned a B.A. in Government from the University of Notre Dame and a J.D. from the Catholic University of America.